Get it on Google Play

FDA approves Incyte's once-daily Jakafi XR for blood disorders

May 1, 2026 5:28 PM EDT Send to a Friend
Incyte Corporation (NASDAQ: INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR (ruxolitinib) extended-release tablets for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login